P3 Health Partners Inc. 8-K

What Happened
P3 Health Partners Inc. (PIII) filed an 8-K (Apr 28, 2026) reporting that on April 27, 2026 it entered into a Debt Exchange Agreement to convert approximately $252,479,967 of outstanding promissory notes (principal, accrued interest, back‑end fees) into several series of non‑voting, non‑convertible cumulative preferred stock with a $100 stated value per share. The company also entered a Series D Purchase Agreement to sell up to $70 million of Units (preferred shares plus warrants); $10 million of Units were sold at the initial closing and $60 million remain available in future tranches. The company says the transactions are intended to restore compliance with Nasdaq Listing Rule 5550(b)(1), which requires $2.5 million minimum stockholders’ equity.

Key Details

• Debt exchange: ~$252,479,967 converted into preferred stock at $100 stated value per share:
  • Series A 13.5%: $49,784,252.30 → 497,843 shares
  • Series B 17.5%: $39,550,272.32 → 395,503 shares
  • Series C 19.5%: $163,145,442.42 → 1,631,456 shares
• Series D financing: up to $70M of Units (preferred + warrants); $10M sold at initial close, $60M available later. Series D dividends equal to Series C (19.5%).
• Preferred terms: cumulative dividends (payable only if declared or upon specified liquidity events), payable in cash or in‑kind at the company’s election; redeemable at $100 per share plus unpaid dividends; non‑voting, non‑convertible, not listed/registered. Preferred stock ranks senior to all common stock for dividends and liquidation.
• Warrants: each Unit includes a warrant exercisable for a number of common shares equal to 0.66333% of outstanding Class A and Class V common stock per $1,000,000 funded; exercise price = Nasdaq Minimum Price at issuance; 7‑year term. Registration rights were granted for resales of common stock issuable on exercise of the warrants.
• Related‑party matters: transactions involve affiliates of Chicago Pacific Founders (CPF); a special committee negotiated and approved the deals. CPF parties received governance and information rights in a Third Amended and Restated Letter Agreement (including the right to designate one independent director while owning 40% of common and an extended standstill through Jan 1, 2027 limiting CPF ownership to 49.99%).

Why It Matters
These filings change P3’s capital structure materially: a large portion of debt is converted into preferred equity, which the company expects will raise reported stockholders’ equity and address Nasdaq’s minimum equity requirement. The preferred shares are senior to common stock for dividends and liquidation but are non‑voting and non‑convertible; warrants issued with Units could result in future issuance of common shares. Investors should note the involvement of CPF (the largest stockholder/debtholder), the special committee approval for related‑party transactions, and the potential for future dilution from the remaining $60M of Units and outstanding warrants.